How Successful Investors Get RICH

Learn everything you need to know in 'The Canadian Guide on How to Invest in Stocks Successfully' for FREE from The Successful Investor.

How to Invest In Stocks Guide: Find 10 factors that make your investments safer and stronger.

 I consent to receiving information from The Successful Investor via email. I understand I can unsubscribe from these updates at any time.

Topic: How To Invest

Gilead fortifies strong position in hepatitis C and HIV/AIDS drugs

investing in stocks

Pat McKeough responds to many requests from members of his Inner Circle for specific advice about investing in stocks as well as questions on investment strategy and the economy. Every week, his comments and recommendations on the most intriguing questions of the past week go out to all Inner Circle members. And each week, we offer you one of the highlights from these Q&A sessions. While we reserve our buy-hold-sell advice for Inner Circle members, these excerpts provide a great deal of information and analysis on stocks we’ve covered for members of Pat’s Inner Circle.

This week an Inner Circle member asked us about a drug company that specializes in combatting viruses. Hepatitis C is the primary target of treatments developed by Gilead Sciences, but it also plays a significant role in treatments for HIV/AIDS. Pat examines the status of the company’s leading drugs and analyzes its ability to maintain a position of leadership in a fiercely competitive field.

Q: Hi Pat: What do you think of Gilead Sciences, a maker of a new antiviral drug that’s very effective against hepatitis C? Thanks.

A: Gilead Sciences Inc. (symbol GILD on Nasdaq; www.gilead.com), discovers, develops and markets treatments for viruses.

The company has a number of drugs on the market, including AmBisome (an antifungal agent), Emtriva (for HIV), Tamiflu (influenza), Vistide (for cytomegalovirus retinitis—or an inflammation of the retina—in AIDS patients) and Hepsera (for hepatitis B).

Hepatitis refers to inflammation of the liver, as well as a group of viral infections that also affect the liver. The most common types are hepatitis A, hepatitis B and hepatitis C. Viral hepatitis is the leading cause of liver cancer and the most common reason why patients need liver transplants.

Gilead has developed a range of treatments to counteract hepatitis C, including its Sovaldi drug, which it started selling in December 2013. Sovaldi is more expensive than its main competitor, but it’s also more effective. This is one of the major reasons why Gilead shares have gained nearly 50% in the past year.

The market for hepatitis treatments is huge, with over 150 million people worldwide suffering from the condition. Hepatitis C is the most common strain and the one Gilead has the most expertise with.

The competition to develop an inexpensive hepatitis C treatment that’s easily administered (in pill form, for example) is intense. Besides Gilead, Abbott Labs, Vertex, Merck and Bristol-Myers have developed oral versions of a hepatitis C product. However, Gilead has about 75% of the worldwide hepatitis C market.

Gilead owns patents on all four drugs comprising leading HIV/AIDS treatment Stribild

The company also has a strong position in treatments for HIV/AIDS, including its Stribild drug combination, which it started selling in the U.S. in August 2012. European regulators approved Stribild in May 2013.

Like Sovaldi, Stribild is more expensive than other treatments but more effective. As well, Gilead holds the patents on all four drugs that comprise Stribild, so it doesn’t have to share the profits with other drug developers.

Gilead has several other promising drugs in its pipeline. For example, it hopes to win regulatory approval to start selling Idelalisib, a new blood cancer therapy, this year. This drug, in combination with another, is safer for patients who aren’t fit for chemotherapy.

In the three months ended March 31, 2014, Gilead’s overall revenue jumped 97.5%, to $5.0 billion from $2.5 billion a year earlier. That’s mainly due to Sovaldi, which contributed $2.3 billion to the latest total. Earnings climbed to $2.5 billion, or $1.48 a share, from $801.9 million, or $0.48.

The company spent $595.0 million (or 11.9% of its revenue) on research in the latest quarter, up 19.6% from $497.6 million (or 19.7%) a year earlier.

Gilead’s long-term debt of $11 billion is 9% of its market cap. It also holds cash of $6.9 billion, or $4.46 a share.

In the Inner Circle Q&A, Pat looks at Gilead’s earnings outlook and its ability to sustain the higher research spending required to keep it ahead of the intense competition in the development of hepatitis C treatments. He concludes with his clear buy-hold-sell advice on this stock.

(Note: If you are a current member of the Inner Circle, please click here to view Pat’s recommendation. Be sure to log in first.)

COMMENTS PLEASE—Share your investment knowledge and opinions with fellow TSINetwork.ca members

Have you ever had a big breakthrough with a pharmaceutical stock that struck it rich with a best-selling drug? Did you keep the stock when patent protection ran out for that particular drug? Was the company able to sustain its momentum after the patent expired?

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.